Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immutep ( (IMMP) ) has provided an announcement.
On August 5, 2025, Immutep Limited announced that it received positive feedback from the FDA regarding the clinical development of its MHC Class II agonist, eftilagimod alfa, for treating recurrent/metastatic head and neck squamous cell carcinoma patients with low PD-L1 expression. The FDA’s support highlights the potential of eftilagimod alfa in combination with KEYTRUDA to address unmet medical needs in this patient segment, paving the way for future clinical trials and potential accelerated approval. This feedback positions Immutep to explore collaborative development paths, potentially enhancing its market position and offering new treatment options for underserved patients.
The most recent analyst rating on (IMMP) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep’s overall stock score reflects the challenges and potential of a biotech firm in its developmental stage. Strong financial stability from a robust balance sheet is offset by negative profitability and cash flow. Technical analysis provides some optimism with balanced momentum signals, but valuation remains a concern due to ongoing losses. This score highlights the high-risk, high-reward nature of investing in early-stage biotech stocks.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep is a late-stage biotechnology company specializing in the development of novel immunotherapies for cancer and autoimmune diseases. The company is a leader in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), with a diverse product portfolio aimed at stimulating or suppressing the immune response to provide innovative treatment options.
Average Trading Volume: 107,527
Technical Sentiment Signal: Sell
Current Market Cap: $253.2M
For detailed information about IMMP stock, go to TipRanks’ Stock Analysis page.